ARHGAP25 | Rho GTPase activating protein 25 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
BCL11B | B-cell CLL/lymphoma 11B (zinc finger protein) | Cancer-related genes Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
C12orf77 | Chromosome 12 open reading frame 77 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CCL21 | Chemokine (C-C motif) ligand 21 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CCR6 | Chemokine (C-C motif) receptor 6 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CD180 | CD180 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD2 | CD2 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD22 | CD22 molecule | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD37 | CD37 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD3D | CD3d molecule, delta (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD3G | CD3g molecule, gamma (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD40LG | CD40 ligand | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD7 | CD7 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD80 | CD80 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD84 | CD84 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD8B | CD8b molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CXCR3 | Chemokine (C-X-C motif) receptor 3 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
DENND1C | DENN/MADD domain containing 1C | Predicted intracellular proteins
| | | | | Tissue enhanced |
FCRL1 | Fc receptor-like 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FYB | FYN binding protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
GP1BA | Glycoprotein Ib (platelet), alpha polypeptide | CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GRAP2 | GRB2-related adaptor protein 2 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
GZMK | Granzyme K (granzyme 3; tryptase II) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
HIST1H3J | Histone cluster 1, H3j | Predicted intracellular proteins
| | | | | Tissue enhanced |
IDO1 | Indoleamine 2,3-dioxygenase 1 | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted intracellular proteins Predicted membrane proteins Transcription factors
| | | | | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAT | Linker for activation of T cells | Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
LCK | LCK proto-oncogene, Src family tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Cytoskeleton related proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
LY86 | Lymphocyte antigen 86 | Predicted secreted proteins
| | | | | Tissue enhanced |
MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MYBL2 | V-myb avian myeloblastosis viral oncogene homolog-like 2 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
NCF1 | Neutrophil cytosolic factor 1 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
PAX5 | Paired box 5 | Cancer-related genes Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |